<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985685</url>
  </required_header>
  <id_info>
    <org_study_id>2013P000240</org_study_id>
    <nct_id>NCT01985685</nct_id>
  </id_info>
  <brief_title>The Effect of Thiamine vs. Placebo on VO2 in Critical Illness</brief_title>
  <acronym>TVO2_RCT</acronym>
  <official_title>The Effect of Thiamine vs. Placebo on VO2 in Critical Illness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Deaconess Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine the effect of thiamine therapy on oxygen
      consumption (VO2) in critically-ill patients. We will evaluate this by measuring VO2 before
      and after thiamine or placebo administration in patients admitted to the ICU and requiring
      mechanical ventilation. A secondary aim is to evaluate the effect of thiamine vs. placebo on
      the metabolic profile of the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Extensive research has been done over the past two decades looking at the role of oxygen
      delivery (DO2) and oxygen utilization (VO2) in critical illness. VO2 depends on cardiac
      output, arterial oxygen content, and the body's ability to extract oxygen effectively from
      the blood. Oxygen demand rises in critical illness as the body goes into a catabolic state,
      and lower VO2 has been associated with higher lactate levels and with poorer outcomes.
      Although increasing DO2 was shown in past studies to raise VO2 in some patients, other
      investigators have found that many critically-ill patients failed to demonstrate a rise in
      VO2 in spite of achieving supranormal values of cardiac index (CI) and DO2. This group, in
      contrast to patients whose VO2 rose with the increase in CI and DO2, had exceedingly poor
      outcomes, suggesting that an inability to extract oxygen from the blood confers a poorer
      prognosis.

      Thiamine deficiency can manifest in several ways, but the syndrome of wet beriberi, caused by
      thiamine deficiency, includes lactic acidosis, cardiac decompensation and vasodilatory shock,
      similar to sepsis and other forms of critical illness. The mechanism by which thiamine
      deficiency causes dysfunction rests upon the vitamin's essential role in the Krebs cycle and
      Pentose Phosphate Pathway. Lack of adequate thiamine results in the failure of pyruvate to
      enter the Krebs Cycle, thus preventing aerobic metabolism. The resulting decrease in aerobic
      metabolism and increase in anaerobic metabolism leads to decreased oxygen consumption by the
      tissues and increased lactic acid production.

      Our group has found previously that upwards of 20% of critically ill patients with sepsis are
      thiamine deficient within 72 hours of presentation. In a dog model of septic shock,
      Lindenbaum et al have shown that, regardless of thiamine levels, supplementation with
      thiamine improved not only lactate clearance and mean arterial pressure, but increased VO2 as
      well. An increase in VO2 max after administration of thiamine to healthy volunteers has also
      been described. In our prior open-label study, we found that the administration of a single
      dose of 200mg of intravenous thiamine to critically ill patients led to a statistically
      significant increase in VO2 in those with normal or elevated cardiac output, suggesting that
      thiamine may increase the extraction component of VO2, even in the absence of absolute
      thiamine deficiency. This effect was not seen in patients with low cardiac output.

      VO2 is known to rise in inflammatory states, reflecting increased energy expenditure. Prior
      studies have shown that VO2 will decrease with interventions such as fever control. In spite
      of VO2 being higher than normal in critically-ill patients, however, the end-organ damage and
      lactic acidosis suggest that it is not high enough to meet the metabolic demands of the
      critically-ill body. If we are able to increase VO2 further in critically-ill patients, we
      could potentially help maintain aerobic metabolism and decrease tissue hypoxia and the
      resulting end-organ damage. Our hypothesis is that administering thiamine intravenously to
      critically-ill patients who do not have abnormally low cardiac index will increase VO2.

      We will use an anesthesia monitor with a gas exchange module to measure VO2 continuously over
      a 9 hour period. After 3 hours of baseline VO2 data are collected, baseline thiamine level,
      lactate, and central venous O2 saturation will be obtained. A single dose of 200mg of IV
      thiamine will then be given, and 6 hours of post-thiamine data will then be collected. We
      will screen all consenting patients for whom we do not know the cardiac index with a
      non-invasive cardiac index measurement using the Cheetah non-invasive cardiac output monitor
      (NICOM). We will not include patients with a cardiac index less than or equal to 2.4L/min/m2,
      due to our preliminary data showing these patients did not increase VO2 in response to
      thiamine. All patients enrolled will have cardiac index monitored continuously during the
      study by the NICOM, in order to assess whether or not there is any relationship between VO2
      and cardiac index. Patients will also have blood drawn for a metabolomic panel before and
      after thiamine or placebo to assess whether thiamine has an effect on the metabolome.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VO2 Over Time</measure>
    <time_frame>6 hrs</time_frame>
    <description>The primary outcome will be the change in VO2 over the 6 hours after administration of the study medication, adjusted for baseline VO2.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage Change in Serum Lactate</measure>
    <time_frame>6 hrs</time_frame>
    <description>Percentage change in serum lactate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Central Venous Oxygen Saturation</measure>
    <time_frame>6 hrs</time_frame>
    <description>Change in central venous oxygen saturation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Critically Ill</condition>
  <condition>Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Thiamine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200mg intravenous thiamine in 50ml 5% dextrose, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50ml intravenous 5% dextrose, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiamine</intervention_name>
    <description>200 mg IV thiamine</description>
    <arm_group_label>Thiamine</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult patients (age &gt; 18 yrs) admitted to an ICU

          2. Mechanically ventilated for an acute illness, with stable respiratory status (no
             changes in ventilator settings in the 3 hours prior to enrollment)

          3. Cardiac index &gt;2.4L/min/m2 as measured by Noninvasive Cardiac Output Monitor(NICOM) by
             Cheetah Medical or, if being used clinically, by PA catheter or Vigileo device.

          4. Upper central venous line in place

        Exclusion Criteria:

          1. Unstable ventilator settings during measurement of VO2

          2. Temperature &gt;100.5

          3. FIO2&gt;60%

          4. Endotracheal cuff leak, chest tube, or other evident source of air leak

          5. Positive end expiratory pressure &gt; 12cmH2O

          6. Intravenous thiamine supplementation within 2 weeks of enrollment, or oral
             supplementation more than that found in a multivitamin.

          7. Protected populations (pregnant woman, prisoners, cognitively impaired)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Berg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Deaconess Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 11, 2013</study_first_submitted>
  <study_first_submitted_qc>November 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <results_first_submitted>September 7, 2017</results_first_submitted>
  <results_first_submitted_qc>September 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2017</results_first_posted>
  <last_update_submitted>September 7, 2017</last_update_submitted>
  <last_update_submitted_qc>September 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beth Israel Deaconess Medical Center</investigator_affiliation>
    <investigator_full_name>Katherine Berg</investigator_full_name>
    <investigator_title>Assistant Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>VO2, critically ill, oxygen consumption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thiamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Thiamine</title>
          <description>200mg intravenous thiamine in 50ml 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>50ml intravenous 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Thiamine</title>
          <description>200mg intravenous thiamine in 50ml 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>50ml intravenous 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="56"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="61" upper_limit="75"/>
                    <measurement group_id="B2" value="66" lower_limit="49" upper_limit="75"/>
                    <measurement group_id="B3" value="67" lower_limit="53" upper_limit="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in VO2 Over Time</title>
        <description>The primary outcome will be the change in VO2 over the 6 hours after administration of the study medication, adjusted for baseline VO2.</description>
        <time_frame>6 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thiamine</title>
            <description>200mg intravenous thiamine in 50ml 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50ml intravenous 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in VO2 Over Time</title>
          <description>The primary outcome will be the change in VO2 over the 6 hours after administration of the study medication, adjusted for baseline VO2.</description>
          <units>ml/kg/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" lower_limit="3.7" upper_limit="5.7"/>
                    <measurement group_id="O2" value="4.3" lower_limit="3.5" upper_limit="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Change in Serum Lactate</title>
        <description>Percentage change in serum lactate</description>
        <time_frame>6 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thiamine</title>
            <description>200mg intravenous thiamine in 50ml 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50ml intravenous 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Change in Serum Lactate</title>
          <description>Percentage change in serum lactate</description>
          <units>percentage change</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9" lower_limit="-17" upper_limit="10"/>
                    <measurement group_id="O2" value="-8" lower_limit="-21" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Central Venous Oxygen Saturation</title>
        <description>Change in central venous oxygen saturation</description>
        <time_frame>6 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Thiamine</title>
            <description>200mg intravenous thiamine in 50ml 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50ml intravenous 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Central Venous Oxygen Saturation</title>
          <description>Change in central venous oxygen saturation</description>
          <units>percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-5" upper_limit="7"/>
                    <measurement group_id="O2" value="3" lower_limit="-4" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All patients were followed for outcomes, including adverse events, until hospital discharge</time_frame>
      <desc>We collected data on mortality, but this was not attributed to study drug in any instance.</desc>
      <group_list>
        <group group_id="E1">
          <title>Thiamine</title>
          <description>200mg intravenous thiamine in 50ml 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>50ml intravenous 5% dextrose, single dose
Thiamine: 200 mg IV thiamine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="29"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>We found differences in variability in VO2 after study drug in the subgroup of patients (35%) who were thiamine deficient.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Katherine Berg</name_or_title>
      <organization>Beth Israel Deaconess Medical Center</organization>
      <phone>617-667-5864</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

